Braftovi | Encorafenib (download only)
Regular price $0.00
A download link will be emailed after check out.
Braftovi (encorafenib) is an anti-cancer medicine, which belongs to a group of medicines called ‘BRAF inhibitors’.
Braftovi can be used in combination with Erbitux (cetuximab) for the targeted treatment of patients with BRAF V600E-variant metastatic bowel cancer who have received prior systemic therapy.
Before you start treatment, your doctor will have tested your tumour to confirm that it has a BRAF mutation.
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Encorafenib has been approved by the Therapeutic Goods Administration (TGA) and is registered on the Australian Register of Therapeutic Goods (ARTG) for use in Australia, however, it is not currently listed on the PBS as a subsidised treatment.